Furthermore, the diagnostic potential of PDL-1, CTLA-4, PD-1, FOXP3, and MIC-B were assessed and revealed that PDL-1, CTLA-4, PD-1, and FOXP3 achieved a specificity of 100% for distinguishing BC patients, at a sensitivity of 93.3%, 82.2%, 62.2%, and 71.1% respectively. This evidence concerns the gene PDCD1 and breast cancer.